Braveheart Bio, Inc. Common Stock (BRVE) - Total Liabilities
Based on the latest financial reports, Braveheart Bio, Inc. Common Stock (BRVE) has total liabilities worth $222.86 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See BRVE current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Braveheart Bio, Inc. Common Stock - Total Liabilities Trend (2025–2025)
This chart illustrates how Braveheart Bio, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. See Braveheart Bio, Inc. Common Stock leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
Braveheart Bio, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Braveheart Bio, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SoftwareONE Holding AG
SW:SWON
|
Switzerland | CHF5.81 Billion |
|
BBMG Corp Class A
SHG:601992
|
China | CN¥174.70 Billion |
|
Shenzhen Hymson Laser Intelligent Equipments Co Ltd
SHG:688559
|
China | CN¥12.61 Billion |
|
LANXESS AG UNSP.ADR 1/5
F:LX9B
|
Germany | €4.28 Billion |
|
S&T Bancorp Inc
NASDAQ:STBA
|
USA | $8.54 Billion |
|
Hope Bancorp Inc
NASDAQ:HOPE
|
USA | $16.70 Billion |
|
Changbai Mountain Tourism Co Ltd
SHG:603099
|
China | CN¥289.34 Million |
|
NCAB Group
ST:NCAB
|
Sweden | Skr2.08 Billion |
Liability Composition Analysis (2025–2025)
This chart breaks down Braveheart Bio, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BRVE total asset value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.76 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Braveheart Bio, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Braveheart Bio, Inc. Common Stock (2025–2025)
The table below shows the annual total liabilities of Braveheart Bio, Inc. Common Stock from 2025 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $155.22 Million | -- |
About Braveheart Bio, Inc. Common Stock
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is he… Read more